No new safety risks were identified in the studies. Positive topline results were announced from the phase 3 SELECT-AXIS 2 study evaluating upadacitinib in adults with active ankylosing spondylitis ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The ...

The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...

Full 1-year results have now been published for the pivotal SELECT-AXIS 2 trial that underpinned the FDA approval of upadacitinib (Rinvoq) for non-radiographic axial spondyloarthritis (axSpA), ...

(RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial ...

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...

Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...

With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...

In recent decades, major advancements have been made in our understanding of ankylosing spondylitis (AS). We now know how to diagnose it and how to manage it better. We can now diagnose AS earlier ...

For patients with axial spondyloarthritis (axSpA) who do not benefit from or cannot take nonsteroidal anti-inflammatory drugs (NSAIDs), new treatment options include agents in multiple drug classes.